The device uses acoustic resonance therapy to alleviate symptoms. Credit: StoryTime Studio / Shutterstock.

SoundHealth has launched SONU, an AI-enabled wearable device for at-home treatment of nasal congestion due to allergic and non-allergic rhinitis in adults.

The over-the-counter device has received De Novo classification from the US Food and Drug Administration (FDA) and uses acoustic resonance therapy to alleviate symptoms.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

SONU operates by generating personalised acoustic vibrations that target nasal congestion, offering a safe alternative to pharmaceutical treatments.

The accompanying SONU app scans the user’s face to map their sinuses and determine the optimal frequencies for treatment.

Once the device is activated, the SONU band emits resonant sound waves to stimulate nasal nerves, leading to decreased swelling and improved mucus clearance.

See Also:

Furthermore, SoundHealth has secured $7m in seed funding to boost the device’s marketing efforts and pursue regulatory approval for additional uses.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The investment round was led by Moai Capital and J4 Ventures, with contributions from TeleSoft Partners, TechU Ventures, Tau Ventures, Rhythm Venture Capital and Peter Moran.

Moran said: “SONU is using the latest medical science to provide a game-changing and liberating alternative treatment for nasal congestion. Investors are increasingly looking for high-efficacy solutions to many maladies without the side effects of pharmaceutical approaches.”

SoundHealth founder and CEO Dr Paramesh Gopi said: “We are delighted to announce the close of our seed-round investment — the proceeds of which will be used for product launch and advancing our pipeline of indications for the SONU device.

“Our groundbreaking technology provides the first FDA-authorised, non-pharmaceutical medical device treatment option for nasal congestion due to allergic and non-allergic rhinitis.”